1292211-30-3

Upstream product

• 100-39-0 benzyl bromide 
• 410544-37-5 5-bromo-8-hydroxy-[1,6]naphthyridine-7-carboxylic acid methyl ester 
• 410545-60-7 methyl 5-bromo-8-p-toluenesulfonyloxy-1,6-naphthyridine-7-carboxylate 
• 1292211-02-9 2-(aminomethyl)-5-fluorobenzoic acid ethyl ester hydrochloride 
• 1292211-29-0 8-(benzyloxy)-5-(5-(tert-butoxycarbonylamino)-N-methylpentylsulfonamido)-1,6-naphthyridine-7-carboxylic acid 
• 1292211-05-2 4-cyano-N-methylbutane-1-sulfonamide 
• 1292211-06-3 5-amino-N-methylpentane-1-sulfonamide 
• 1292211-07-4 tert-butyl 5-(N-methylsulfamoyl)pentylcarbamate 
• 1292211-26-7 methyl 5-(5-((tert-butoxycarbonyl)amino)-N-methylpentylsulfonamido)-8-(tosyloxy)-1,6-naphthyridine-7-carboxylate 
• 1292211-27-8 methyl 5-(5-(tert-butoxycarbonylamino)-N-methylpentylsulfonamido)-8-hydroxy-1,6-naphthyridine-7-carboxylate 
• 1292211-28-9 methyl 8-(benzyloxy)-5-(5-(tert-butoxycarbonylamino)-N-methylpentyl-sulfonamido)-1,6-naphthyridine-7-carboxylate 

Downstream Products

• 1292211-31-4 2-((5-(5-amino-N-methylpentylsulfonamido)-8-hydroxy-1,6-naphthyridine-7-carboxamido)methyl)-5-fluorobenzoic acid hydrochloride 

Relevant academic research and scientific papers

Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus

This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS

This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.